Sodium alginate ameliorates indomethacin-induced gastrointestinal mucosal injury via inhibiting translocation in rats

World Journal of Gastroenterology

Volumn 20, Issue 10, 2014, Pages 2641-2652

  Yamamoto, Atsuki ^a,b   Itoh, Tomokazu ^a,c   Nasu, Reishi ^a   Nishida, Ryuichi ^a,c  

^a Pharmaceutical Division   (Japan)

^b KATAYAMA SEIYAKUSYO Co Ltd   (Japan)

^c Kaigen Pharma Co Ltd   (Japan)

Author keywords

Bacterial translocation; Gastrointestinal mucosal injury; Mucin; Non steroidal anti inflammatory drugs; Sodium alginate

Indexed keywords

ALGINIC ACID; CATALASE; GLUTATHIONE PEROXIDASE; INDOMETACIN; MUCIN; MYELOPEROXIDASE; REBAMIPIDE; SUPEROXIDE DISMUTASE; ANTIULCER AGENT; BIOLOGICAL MARKER; GLUCURONIC ACID; HEXURONIC ACID; PEROXIDASE;

ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BACTERIAL COUNT; BACTERIAL TRANSLOCATION; BLOOD VESSEL PERMEABILITY; CONTROLLED STUDY; ENTEROBACTERIACEAE; ENZYME ACTIVITY; ERYTHROCYTE COUNT; GASTROINTESTINAL MUCOSA; INTESTINE ABSORPTION; LEUKOCYTE COUNT; NONHUMAN; RAT; SMALL INTESTINE; STOMACH LESION; STOMACH MUCOSA INJURY; ANEMIA; ANIMAL; ATROPHY; BLOOD; CAPILLARY PERMEABILITY; CELL PROTECTION; CHEMICALLY INDUCED; DISEASE MODEL; DRUG EFFECTS; ENTERITIS; INTESTINE MUCOSA; MALE; METABOLISM; MICROBIOLOGY; PATHOLOGY; SPRAGUE DAWLEY RAT; STOMACH MUCOSA; STOMACH ULCER;

ALGINATES; ANEMIA; ANIMALS; ANTI-ULCER AGENTS; ATROPHY; BACTERIAL TRANSLOCATION; BIOLOGICAL MARKERS; CAPILLARY PERMEABILITY; CATALASE; CYTOPROTECTION; DISEASE MODELS, ANIMAL; ENTERITIS; GASTRIC MUCOSA; GLUCURONIC ACID; GLUTATHIONE PEROXIDASE; HEXURONIC ACIDS; INDOMETHACIN; INTESTINAL MUCOSA; INTESTINE, SMALL; MALE; PEROXIDASE; RATS, SPRAGUE-DAWLEY; STOMACH ULCER; SUPEROXIDE DISMUTASE;

EID: 84896872463     PISSN: 10079327     EISSN: 22192840     Source Type: Journal    
DOI: 10.3748/wjg.v20.i10.2641     Document Type: Article

References (40)

1. Hatazawa R, Ohno R, Tanigami M, Tanaka A, Takeuchi K. Roles of endogenous prostaglandins and cyclooxygenase isozymes in healing of indomethacin-induced small intestinal lesions in rats. J Pharmacol Exp Ther 2006; 318: 691-699 [PMID: 16699067 DOI: 10.1124/jpet.106.103994]
2. Graham DY, Opekun AR, Willingham FF, Qureshi WA. Visible small-intestinal mucosal injury in chronic NSAID users. Clin Gastroenterol Hepatol 2005; 3: 55-59 [PMID: 15645405 DOI: 10.1016/S1542-3565(04)00603-2]
3. Rimbaş M, Marinescu M, Voiosu MR, Bǎicuş CR, Caraiola S, Nicolau A, Niţescu D, Badea GC, Pârvu MI. NSAID-induced deleterious effects on the proximal and mid small bowel in seronegative spondyloarthropathy patients. World J Gastroenterol 2011; 17: 1030-1035 [PMID: 21448355 DOI: 10.3748/wjg. v17.i8.1030]
4. Higuchi K, Umegaki E, Watanabe T, Yoda Y, Morita E, Murano M, Tokioka S, Arakawa T. Present status and strategy of NSAIDs-induced small bowel injury. J Gastroenterol 2009; 44: 879-888 [PMID: 19568687 DOI: 10.1007/s00535-009-0102-2]
5. Anthony A, Pounder RE, Dhillon AP, Wakefield AJ. Vascular anatomy defines sites of indomethacin induced jejunal ulceration along the mesenteric margin. Gut 1997; 41: 763-770 [PMID: 9462208 DOI: 10.1136/gut.41.6.763]
6. Takeuchi K, Miyazawa T, Tanaka A, Kato S, Kunikata T. Pathogenic importance of intestinal hypermotility in NSAIDinduced small intestinal damage in rats. Digestion 2002; 66: 30-41 [PMID: 12379813 DOI: 10.1159/000064419]
7. Porras M, Martín MT, Yang PC, Jury J, Perdue MH, Vergara P. Correlation between cyclical epithelial barrier dysfunction and bacterial translocation in the relapses of intestinal inflammation. Inflamm Bowel Dis 2006; 12: 843-852 [PMID: 16954803 DOI: 10.1097/01.mib.0000231571.88806.62]
8. Okayama T, Yoshida N, Uchiyama K, Takagi T, Ichikawa H, Yoshikawa T. Mast cells are involved in the pathogenesis of indomethacin-induced rat enteritis. J Gastroenterol 2009; 44 Suppl 19: 35-39 [PMID: 19148791 DOI: 10.1007/s00535-008-2267-5]
9. Omatsu T, Naito Y, Handa O, Mizushima K, Hayashi N, Qin Y, Harusato A, Hirata I, Kishimoto E, Okada H, Uchiyama K, Ishikawa T, Takagi T, Yagi N, Kokura S, Ichikawa H, Yoshikawa T. Reactive oxygen species-quenching and antiapoptotic effect of polaprezinc on indomethacin-induced small intestinal epithelial cell injury. J Gastroenterol 2010; 45: 692-702 [PMID: 20174833 DOI: 10.1007/s00535-010-0213-9]
10. Kunikata T, Tanaka A, Miyazawa T, Kato S, Takeuchi K. 16,16-Dimethyl prostaglandin E2 inhibits indomethacininduced small intestinal lesions through EP3 and EP4 receptors. Dig Dis Sci 2002; 47: 894-904 [PMID: 11991626 DOI: 10.1023/A:1014725024519]
11. Scheiman JM, Yeomans ND, Talley NJ, Vakil N, Chan FK, Tulassay Z, Rainoldi JL, Szczepanski L, Ung KA, Kleczkowski D, Ahlbom H, Naesdal J, Hawkey C. Prevention of ulcers by esomeprazole in at-risk patients using non-selective NSAIDs and COX-2 inhibitors. Am J Gastroenterol 2006; 101: 701-710 [PMID: 16494585 DOI: 10.1111/j.1572-0241.2006.00499.x]
12. Maiden L, Thjodleifsson B, Theodors A, Gonzalez J, Bjarnason I. A quantitative analysis of NSAID-induced small bowel pathology by capsule enteroscopy. Gastroenterology 2005; 128: 1172-1178 [PMID: 15887101 DOI: 10.1053/j.gastro.2005.03.020]
13. Goldstein JL, Eisen GM, Lewis B, Gralnek IM, Zlotnick S, Fort JG. Video capsule endoscopy to prospectively assess small bowel injury with celecoxib, naproxen plus omeprazole, and placebo. Clin Gastroenterol Hepatol 2005; 3: 133-141 [PMID: 15704047 DOI: 10.1016/S1542-3565(04)00619-6]
14. Wallace JL, Syer S, Denou E, de Palma G, Vong L, McKnight W, Jury J, Bolla M, Bercik P, Collins SM, Verdu E, Ongini E. Proton pump inhibitors exacerbate NSAID-induced small intestinal injury by inducing dysbiosis. Gastroenterology 2011; 141: 1314-1322, 1322. e1-5 [PMID: 21745447 DOI: 10.1053/ j.gastro.2011.06.075]
15. Mizukami K, Murakami K, Abe T, Inoue K, Uchida M, Okimoto T, Kodama M, Fujioka T. Aspirin-induced small bowel injuries and the preventive effect of rebamipide. World J Gastroenterol 2011; 17: 5117-5122 [PMID: 22171147 DOI: 10.3748/ wjg.v17.i46.5117]
16. Diao L, Mei Q, Xu JM, Liu XC, Hu J, Jin J, Yao Q, Chen ML. Rebamipide suppresses diclofenac-induced intestinal permeability via mitochondrial protection in mice. World J Gastroenterol 2012; 18: 1059-1066 [PMID: 22416180 DOI: 10.3748/ wjg.v18.i10.1059]
17. Daigo K, Wada Y, Yamada C, Yamaji M, Okuda S, Okada M, Miyazato T. [Pharmacological studies of sodium alginate. I. Protective effect of sodium alginate on mucous membranes of upper-gastrointestinal tract]. Yakugaku Zasshi 1981; 101: 452-457 [PMID: 6793708]
18. Daigo K, Yamada C, Wada Y, Yamaji M, Okuda S, Okada M, Miyazato T. [Pharmacological studies of sodium alginate. II. Hemostatic effect of sodium alginate on gastrointestinal bleeding]. Yakugaku Zasshi 1981; 101: 458-463 [PMID: 6974775]
19. Daigo K, Yamaji M, Yamada C, Wada Y, Okuda S, Okada M, Miyazato T. Pharmacological studies of sodium alginate. III. Acceleration of fibrin formation by sodium alginate. Yakugaku Zasshi 1981; 101: 464-469 [PMID: 7288587]
20. Diago K, Yamada C, Yamaji M, Nakagiri N, Okada M, Komiya H, Horiuchi Y, Miyazato T. [Pharmacological studies of sodium alginate. V. Effect of sodium alginate on platelet aggregation]. Yakugaku Zasshi 1985; 105: 171-182 [PMID: 4009424]
21. Poynard T, Vernisse B, Agostini H. Randomized, multicentre comparison of sodium alginate and cisapride in the symptomatic treatment of uncomplicated gastro-oesophageal reflux. Aliment Pharmacol Ther 1998; 12: 159-165 [PMID: 9692690 DOI: 10.1046/j.1365-2036.1998.00283.x]
22. Dettmar PW, Sykes J, Little SL, Bryan J. Rapid onset of effect of sodium alginate on gastro-oesophageal reflux compared with ranitidine and omeprazole, and relationship between symptoms and reflux episodes. Int J Clin Pract 2006; 60: 275-283 [PMID: 16494641 DOI: 10.1111/j.1368-5031.2006.00800.x]
23. Manabe N, Haruma K, Ito M, Takahashi N, Takasugi H, Wada Y, Nakata H, Katoh T, Miyamoto M, Tanaka S. Efficacy of adding sodium alginate to omeprazole in patients with nonerosive reflux disease: a randomized clinical trial. Dis Esophagus 2012; 25: 373-380 [PMID: 22050449 DOI: 10.1111/ j.1442-2050.2011.01276.x]
24. Humphreys ER, Triffitt JT. Absorption by the rat of alginate labelled with carbon-14. Nature 1968; 219: 1172-1173 [PMID: 5675640 DOI: 10.1038/2191172a0]
25. Mirshafiey A, Khodadadi A, Rehm BH, Khorramizadeh MR, Eslami MB, Razavi A, Saadat F. Sodium alginate as a novel therapeutic option in experimental colitis. Scand J Immunol 2005; 61: 316-321 [PMID: 15853913 DOI: 10.1111/j.1365-3083.2005.01571.x]
26. Razavi A, Khodadadi A, Eslami MB, Eshraghi S, Mirshafiey A. Therapeutic effect of sodium alginate in experimental chronic ulcerative colitis. Iran J Allergy Asthma Immunol 2008; 7: 13-18 [PMID: 18322307]
27. Nakatsugawa S, Yukawa Y, Abe M. [Radioprotective effects of sodium alginate on radiation induced intestinal damage]. Nihon Gan Chiryo Gakkai Shi 1988; 23: 1025-1030 [PMID: 3418212]
28. Oshitani T, Okada K, Kushima T, Suematsu T, Obayashi K, Hirata Y, Takada Y, Ishida T, Yoshida M, Narabayashi I. [Clinical evaluation of sodium alginate on oral mucositis associated with radiotherapy]. Nihon Gan Chiryo Gakkai Shi 1990; 25: 1129-1137 [PMID: 2398298]
29. Mizoguchi H, Ogawa Y, Kanatsu K, Tanaka A, Kato S, Takeuchi K. Protective effect of rebamipide on indomethacin-induced intestinal damage in rats. J Gastroenterol Hepatol 2001; 16: 1112-1119 [PMID: 11686837 DOI: 10.1046/j.1440-1746.2001.02592.x]
30. Daigo K, Yamaji M, Yamada C, Matsutani K, Yagi M, Nakajima Y. Curative effect of sodium alginate on experimental hydrochloric acid and tetra-gastrin induced ulcer. Japanese Pharmacol Ther 1982; 10: 281-289
31. Davies NM, Saleh JY, Skjodt NM. Detection and prevention of NSAID-induced enteropathy. J Pharm Pharm Sci 2000; 3: 137-155 [PMID: 10954683]
32. Tugendreich S, Pearson CI, Sagartz J, Jarnagin K, Kolaja K. NSAID-induced acute phase response is due to increased intestinal permeability and characterized by early and consistent alterations in hepatic gene expression. Toxicol Pathol 2006; 34: 168-179 [PMID: 16642600 DOI: 10.1080/0192623060 0611752]
33. Allen A, Flemström G. Gastroduodenal mucus bicarbonate barrier: protection against acid and pepsin. Am J Physiol Cell Physiol 2005; 288: C1-19 [PMID: 15591243]
34. Allen A. Structure of gastrointestinal mucus glycoproteins and the viscous and gel-forming properties of mucus. Br Med Bull 1978; 34: 28-33 [PMID: 342045]
35. Iwai T, Ichikawa T, Goso Y, Ikezawa T, Saegusa Y, Okayasu I, Saigenji K, Ishihara K. Effects of indomethacin on the rat small intestinal mucosa: immunohistochemical and biochemical studies using anti-mucin monoclonal antibodies. J Gastroenterol 2009; 44: 277-284 [PMID: 19280111 DOI: 10.1007/s00535-009-0007-0]
36. Iwai T, Ichikawa T, Kida M, Goso Y, Saegusa Y, Okayasu I, Saigenji K, Ishihara K. Vulnerable sites and changes in mucin in the rat small intestine after non-steroidal anti-inflammatory drugs administration. Dig Dis Sci 2010; 55: 3369-3376 [PMID: 20300842 DOI: 10.1007/s10620-010-1185-6]
37. Barcelo A, Claustre J, Moro F, Chayvialle JA, Cuber JC, Plaisancié P. Mucin secretion is modulated by luminal factors in the isolated vascularly perfused rat colon. Gut 2000; 46: 218-224 [PMID: 10644316 DOI: 10.1136/gut.46.2.218]
38. Sharma R, Young C, Neu J. Molecular modulation of intestinal epithelial barrier: contribution of microbiota. J Biomed Biotechnol 2010; 2010: 305879 [PMID: 20150966]
39. Frankel W, Zhang W, Singh A, Bain A, Satchithanandam S, Klurfeld D, Rombeau J. Fiber: effect on bacterial translocation and intestinal mucin content. World J Surg 1995; 19: 144-148; discussion 148-149 [PMID: 7740802 DOI: 10.1007/BF00317001]
40. Satoh H. Role of dietary fiber in formation and prevention of small intestinal ulcers induced by nonsteroidal anti-inflammatory drug. Curr Pharm Des 2010; 16: 1209-1213 [PMID: 20166992 DOI: 10.2174/138161210790945922]